RANIMUSTINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H18ClN3O7
Molecular Weight	327.719
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=AHHFEZNOXOZZQA-ZEBDFXRSSA-N

InChI=1S/C10H18ClN3O7/c1-20-9-8(17)7(16)6(15)5(21-9)4-12-10(18)14(13-19)3-2-11/h5-9,15-17H,2-4H2,1H3,(H,12,18)/t5-,6-,7+,8-,9+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C10H18ClN3O7
Molecular Weight	327.719
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.genome.jp/dbget-bin/www_bget?D01760
Curator's Comment: Description was created based on several sources, including DOI: 10.1007/978-3-319-13278-5 Retrieved from Molecular Therapies of Cancer By Georg F. Weber, p.26 and http://www.ncbi.nlm.nih.gov/pubmed/2405779

Ranimustine (tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera. It has never been filed for FDA evaluation in the United States, where it is not marketed.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cell growth 21 Target ID: GO:0016049 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9625826	Inhibitor 8297
DNA synthesis involved in DNA replication 7 Target ID: GO:0090592 Sources: http://www.genome.jp/dbget-bin/www_bget?D01760	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic myelogenous leukemia 22 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2817908	Primary		Approved 8429	Cymerin Approved Use Polycythemia vera treatment medicines Launch Date 2014
Polycythemia vera 15 Sources: http://drugs-about.com/drugs-c/cymerin.html	Primary		Approved 8429	Cymerin Approved Use Polycythemia vera treatment medicines Launch Date 2014

PubMed

Title	Date	PubMed
[Perioperative management for radical esophagectomy in a patient with polycythemia vera].	2001 Dec	11797364
Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM).	2001 Jul	11497396
A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.	2001 May	11380402
[A case of chronic thromboembolic pulmonary hypertension based on essential thrombocythemia].	2002 Jul	12382421
Combination chemotherapy of ranimustine, doxorubicine, and dexamethasone for relapsing multiple myeloma--a pilot study.	2003	17682310
Successful high-dose chemotherapy for widespread neuroaxis dissemination of an optico-hypothalamic juvenile pilocytic astrocytoma in an infant: a case report.	2003 May	12777080
Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.	2003 Nov-Dec	14666736
Infrainguinal bypass surgery for chronic arterial occlusive disease associated with essential thrombocythemia: report of a case.	2004	15221564
[Granulocyte-colony stimulating factor-producing myeloma with clinical manifestations mimicking chronic neutrophilic leukemia].	2004 Mar	15103937
[Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].	2005 Apr	16444959
Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma.	2006 Nov-Dec	17195453
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.	2007 Dec 1	17968021
Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma.	2009	19204798
Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.	2009	19145056
[Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].	2009 Mar	19352088
Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma.	2009 Nov	20009441
[Plasmacytoma of chest wall].	2010 Sep	20845698

Patents

Sample Use Guides

In Vivo Use Guide

oral administration of 50mg (one tablet)/body/day every 4-6 days was considered as one course, and this was repeated at 6-8-week intervals if possible

Route of Administration: Oral

In Vitro Use Guide

The SD10 (10% survival dose) of the cells to Ranimustine ranged from 4.3 uM (C6-2 cells) to 151.7 uM (T98G cells).

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:20:06 GMT 2023` Edited by `admin` on `Sat Dec 16 16:20:06 GMT 2023`
Record UNII	RYH2T97J77
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RANIMUSTINE

Official Name

English

RANIMUSTINE [MART.]

Common Name

English

Ranimustine [WHO-DD]

Common Name

English

METHYL 6-(3-(2-CHLOROETHYL)-3-NITROSOUREIDO)-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSIDE

Common Name

English

RANIMUSTINE [JAN]

Common Name

English

RANIMUSTINE [MI]

Common Name

English

NSC-270516

Code

English

CYMERIN

Brand Name

English

ranimustine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C699